Neoprobe signs distribution deal with Syncor International (US)
This article was originally published in Clinica
Syncor International (US) is to distribute Neoprobe's RIGScan cancer detection radiopharmaceuticals in North America and other selected countries. Neoprobe plans to prepare marketing submissions for its first RIGScan product, CR49, in the US by the end of this year, with European dossiers ready for the first quarter of 1996. The RIGScan CR49 is a radiolabelled monoclonal antibody which targets specific antigens produced by colorectal cancer.
You may also be interested in...
Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”
The EU’s new health commissioner, Stella Kyriakides, has outlined the commission’s plans for dealing with medicines access issues in the EU member states. They include completing the review of the EU pediatric and orphan legislation and developing a new strategic plan to tackle shortages and affordability problems next year.
Execs On The Move: Owens & Minor And MicroPort See Big Departures; Dynatronics CEO Moving To BrainsWay
Owens & Minor finance boss joins drug-delivery device maker Intersect ENT; operations VP at MicroPort joins bioprosthetic heart maker Carmat; Dynatronics CEO will head neuromodulation product firm BrainsWay in January; and more.